Nyxoah (NASDAQ:NYXH) versus Carmell (NASDAQ:CTCX) Critical Review

Carmell (NASDAQ:CTCX) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares Carmell and Nyxoah”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carmell	$32,839.00	141.83	-$15.44 million	N/A	N/A
Nyxoah	$4.52 million	83.25	-$46.77 million	($1.95)	-5.67

Carmell has higher earnings, but lower revenue than Nyxoah.

Insider & Institutional Ownership

24.2% of Carmell shares are owned by institutional investors. 29.0% of Carmell shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Carmell and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-217.50%	-50.22%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Carmell and Nyxoah, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carmell	0	0	0	0	0.00
Nyxoah	0	0	4	0	3.00

Nyxoah has a consensus target price of $15.25, suggesting a potential upside of 38.01%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than Carmell.

Risk & Volatility

Carmell has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Summary

Nyxoah beats Carmell on 7 of the 12 factors compared between the two stocks.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.